Advancing Product Candidates
from Our Own Pipeline
A Simple Elegant Solution for Addressing Challenges in Drug Delivery
Actively Partnering with
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration.
Improving health with uniform drug particles
Liquidia precisely engineers drug particles in a virtually unlimited number of ways to transform the lives of patients. Watch the video to see how we do it. The precision of our PRINT technology is designed to improve the safety, efficacy and performance of a wide range of therapies, while reducing manufacturing complexity and cost.